SeromYx Systems to present at World Vaccine & Immunotherapy 30- Nov – 2 Dec 2021, Loews Coronado Bay Resort, San Diego. Dr. Todd Suscovich, SeromYx’s Chief Technical Officer will be presenting on how data from Systems Serology studies guided the development of mAb therapies for CoV2.
World Vaccine & Immunotherapy
Nov 30 – Dec 2, 2021
SeromYx Systems participates at the Immuno-Oncology Summit, Westin Copley Place, Boston. Kaustuv Banerjee, Director, Scientific Development will be talking to participants with the objective of understanding how Systems Serology could benefit Oncology programs.
Oct 4-5, 2021
Founder Galit Alter featured as one of the Boston Globe’s 2020 Bostonians of the Year
Boston Globe Dec 13 2020
Identify the mechanistic immune markers associated with natural infection (disease outcome), vaccination, or treatment.
Screening therapeutic monoclonal antibodies for desired function.
Development of vaccine design strategies (e.g., prime/boost, dose and timing (e.g., delayed fractional dose), adjuvants)
Assay Development, Qualification, Validation
Which assays need to be demonstrated to be statistically robust so that data from them can be included in regulatory filings?